Cas9 News and Research

RSS

IDT releases new ultra-high performance CRISPR Cas12a enzyme

As an advocate for the needs of researchers working at the forefronts of genomic research, Integrated DNA Technologies releases its latest CRISPR enzyme Alt-R® Cas12a Ultra.

From Integrated DNA Technologies 31 May 2019

Scientists use gold nanoparticles to edit genes tied to HIV, inherited blood disorders

Scientists at Fred Hutchinson Cancer Research Center took a step toward making gene therapy more practical by simplifying the way gene-editing instructions are delivered to cells.

28 May 2019

Researchers develop simple, quick technique for gene editing in rice blast fungus

CRISPR/Cas9 is now a household name associated with genetic engineering studies.

24 May 2019

Newly discovered molecules safely halt the gene editing process

Scientists have discovered two non-toxic molecules that safely halt the CRISPR-Cas9 gene editing process.

22 May 2019

CRISPR uncovers which gene fusions are critical for growth of cancer cells

In the first large-scale analysis of cancer gene fusions, which result from the merging of two previously separate genes, researchers at the Wellcome Sanger Institute, EMBL-EBI, Open Targets, GSK and their collaborators have used CRISPR to uncover which gene fusions are critical for the growth of cancer cells.

16 May 2019

Scientists unravel how intelligent neural network predicts the functions of proteins

Intelligent virtual companions like Alexa, Siri, and Google Assistant have long become integrated into our everyday lives. And intelligent computational programs, so-called algorithms, have also evolved as an integral tool in scientific research.

16 May 2019

Form drives function in cancer proliferation, UTSW study finds

A new study finds that the protein responsible for the crawling movements of cells also drives the ability of cancer cells to grow when under stress.

6 May 2019

Discovery of small-molecule inhibitors could enable precise control over CRISPR-Cas9 genome editing

The discovery of the first small-molecule inhibitors of the Streptococcus pyogenes Cas9 (SpCas9) protein could enable more precise control over CRISPR-Cas9-based genome editing, researchers report May 2 in the journal Cell.

3 May 2019

Novel chemical probe enables live imaging of brain immune cells

Researchers in South Korea and Singapore have, for the first time, developed a chemical probe that enables live-imaging of a type of immune cells in the brain, known as microglia, in a live animal brain.

3 May 2019

Researchers uncover potential clue to halt destruction of nerve cells in people with ALS

A special focus on rogue proteins may hold future promise in stopping the progression of nerve cell destruction in people who have amyotrophic lateral sclerosis or frontotemporal dementia.

24 Apr 2019

Scientists deploy CRISPR gene-editing tool to engineer multiple edits

Scientists at Christiana Care Health System's Gene Editing Institute and NovellusDx, an Israeli biotechnology company, have deployed a breakthrough CRISPR gene-editing tool to successfully engineer multiple edits simultaneously to fragments of DNA extracted from a human cell, according to a new study published today in The CRISPR Journal.

19 Apr 2019

Two new epigenetic regulators maintain self-renewal of embryonic stem cells

Embryonic stem cells have the ability to self-renew, and, being pluripotent have the potential to create almost any cell type in the body.

19 Apr 2019

Study describes vulnerability shared by large subset of cancer cell lines

Cancer cells adapt to potentially fatal mutations and other molecular malfunctions by adjusting one or more other genes' activity, in the process becoming dependent on those genes for their survival and growth.

12 Apr 2019

Hundreds of new anti-cancer drug targets identified using CRISPR

A team of scientists from the Wellcome Sanger Institute have identified the genes that are essential for the survival of thirty types of cancer cells.

11 Apr 2019

New strategy for editing and repairing genetic mutation associated with microduplications

Scientists at UMass Medical School have developed a strategy for editing and repairing a particular type of genetic mutation associated with microduplications using CRISPR/Cas9 and a seldom-used DNA repair pathway.

11 Apr 2019

Scientists develop new CRISPR-based 'allelic drive'

New CRISPR-based gene drives and broader active genetics technologies are revolutionizing the way scientists engineer the transfer of specific traits from one generation to another.

10 Apr 2019

Study demonstrates viability of gene editing strategy for recessive dystrophic epidermolysis bullosa

A group of researchers from the Centro de Investigación Biomédica en Red de Enfermedades Raras, Universidad Carlos III de Madrid, the Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, and the Instituto de Investigación Sanitaria Fundación Jiménez Díaz have led a study which demonstrates the viability of a gene editing strategy for recessive dystrophic epidermolysis bullosa (also known as butterfly chilidren) with the tool CRISPR/Cas9 in preclinical models with this disease.

8 Apr 2019

New technology could change the way gene editing is approached in future

Gene editing has been a much sought after and controversial technology. Last month, part of the World Health Organization called for an international registry to track all research into editing the human genome.

4 Apr 2019

Researchers discover how mosquitoes smell acidic volatiles in human sweat

Female mosquitoes are known to rely on an array of sensory information to find people to bite, picking up on carbon dioxide, body odor, heat, moisture, and visual cues.

29 Mar 2019

Researchers develop new strategy to treat sickle cell disease and beta thalassemia

Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and the University of Massachusetts Medical School have developed a strategy to treat two of the most common inherited blood diseases -- sickle cell disease and beta thalassemia -- applying CRISPR-Cas9 gene editing to patients' own blood stem cells.